InvestorsHub Logo
Followers 8
Posts 1891
Boards Moderated 0
Alias Born 05/05/2016

Re: FDApproved post# 14974

Friday, 08/17/2018 9:38:00 AM

Friday, August 17, 2018 9:38:00 AM

Post# of 44784
Very interesting, and, very relevant for Pluristem:

(from) European Commission’s Horizon 2020 research and innovation plan:

Alongside the Cell and Gene Therapy Catapult, the founding partners of the RESTORE consortium comprise world leaders across academia, clinical research and industry, including Charité Universitätsmedizin Berlin (Germany), INSERM – Institut National de la Santé et de la Recherche (France), University of Zurich (Switzerland), Miltenyi Biotec GmbH (Germany), TissUse GmbH (Germany), Pluristem Ltd (Israel), Fondazione Telethon (Italy), University Minho (Portugal) and Innovation Acta S.r.l. (Italy).

Clearly, Pluristem is part of the most important avant-garde in the most important new medical paradigm, i.e. harnessing the power of stem cells as therapeutic agents. Note that the article includes Pluristem in a very exclusive club: world leaders across academia, clinical research and industry

Thanks for the link Allo!

PS: I just noticed that the same paragraph was already excerpted by Allo in the next post, but I'll leave this anyway, I think it's very important to appreciate the arena Pluristem is playing in!